ABSTRACT The only tuberculosis (TB) vaccine in use today, bacillus Calmette-Guérin (BCG), provides insufficient protection and can cause adverse events in immunocompromised individuals, such as BCGosis in HIV ؉ newborns. We previously reported improved preclinical efficacy and safety of the recombinant vaccine candidate BCG ⌬ureC::hly, which secretes the pore-forming listeriolysin O of Listeria monocytogenes. Here, we evaluate a second-generation construct, BCG ⌬ureC::hly ⌬pdx1, which is deficient in pyridoxine synthase, an enzyme that is required for biosynthesis of the essential cofactor vitamin B 6 . This candidate was auxotrophic for vitamin B 6 in a concentration-dependent manner, as was its survival in vivo. BCG ⌬ureC::hly ⌬pdx1 showed markedly restricted dissemination in subcutaneously vaccinated mice, which was ameliorated by dietary supplementation with vitamin B 6 . The construct was safer in severe combined immunodeficiency mice than the parental BCG ⌬ureC::hly. 
Auxotrophic mutants have been explored as potential vaccine candidates for more than a decade (7, 8) . Although the auxotroph M. tuberculosis ⌬panCD, which fails to synthesize vitamin B 5 (pantothenic acid), was markedly attenuated, subcutaneous (s.c.) vaccination of mice provided short-term (28 days) protection against M. tuberculosis challenge comparable to that afforded by BCG (9) . To address safety concerns, notably reversion of a single mutation to full virulence, a second, independent attenuating mutation (leuD gene) was included (10) . The protection induced by the double auxotroph M. tuberculosis ⌬leuD ⌬panCD was comparable to that of BCG in guinea pigs, but booster immunization with the same construct did not improve efficacy in this model (10) . Several other auxotrophic mutants have been tested as TB vaccines either alone (11, 12) or in combination (13, 14) . Although auxotrophic constructs have shown improved safety in preclinical models, they collectively failed to provide better protection than canonical BCG.
Vitamin B 6 is a water-soluble essential cofactor for humans, which in humans must be supplied by dietary intake. In contrast, plants, fungi, and bacteria, including M. tuberculosis, synthesize pyridoxal-5=-phosphate (PLP), the bioactive form of vitamin B 6 , from glutamine and derivatives of the carbohydrate metabolism in a two-step reaction catalyzed by Pdx1 (Rv2606c) and Pdx2 (Rv2604c) (15) . Both proteins form a functional class I glutamine amidotransferase (16, 17) . The protein sequences and crystal structures of Pdx1 orthologs from Bacillus subtilis, Plasmodium species, Saccharomyces cerevisiae, and M. tuberculosis are highly similar, suggesting evolutionary conservation (18) (19) (20) (21) . Deletion of the pdx1 gene renders M. tuberculosis auxotrophic for vitamin B 6 and markedly compromises persistence in mice (15) .
We previously engineered BCG to secrete pore-forming listeriolysin O (Hly) of L. monocytogenes (22) . BCG ⌬ureC::hly (VPM1002) showed superior protection and safety compared to the results for BCG in preclinical models and proved to be safe and immunogenic in humans (22, 23) . VPM1002 has successfully completed phase IIa clinical assessment in newborns (http:// ClinicalTrials.gov identifier NCT01479972). Here, we deleted pdx1 in the genetic background of BCG ⌬ureC::hly to further improve its safety. The immunogenicity, protective capacity, and safety of the new construct, BCG ⌬ureC::hly ⌬pdx1, were evaluated in mice that received either a normal or vitamin B 6 -enriched diet. Our studies provide an innovative basis for novel vaccination strategies in immunocompromised individuals.
RESULTS

Disruption of pdx1 renders BCG auxotrophic for vitamin B 6 .
The pdx1 loss-of-function mutant of M. tuberculosis was shown to be fully auxotrophic for vitamin B 6 (15) . The operon consisting of pdx1 (also called snzP, Rv2606c, and BCG2631c), tesB2 (also called Rv2605c and BCG2630c), and pdx2 (also called snoP, Rv2604c, and BCG2629c) encodes the functional vitamin B 6 synthase complex composed of Pdx1 and Pdx2 and is identical in M. tuberculosis and BCG (see Fig. S1 in the supplemental material) (24, 25) . Thus, we expected a phenotype for a pdx1 knockout in BCG similar to that described for M. tuberculosis (15) . Indeed, disruption of pdx1 by allelic exchange prevented the growth of BCG ⌬ureC::hly in vitamin B 6 -free culture medium (Fig. 1A) . Replication of bacilli was fully restored when cultures were supplemented with 5 M B 6 vitamer pyridoxine. Lower pyridoxine concentrations resulted in suboptimal growth rates of the pdx1 mutant, demonstrating concentration-dependent complementation. Moreover, genetic complementation of the mutant with a functional copy of pdx1 under the control of its native promoter completely reversed the observed growth defect in minimal medium (Fig. 1B) . Altogether, deletion of pdx1 rendered BCG auxotrophic for vitamin B 6 , and this phenotype could be reverted by chemical and genetic means.
Dissemination and survival of BCG ⌬ureC::hly ⌬pdx1 in mice is profoundly compromised. The spread and survival of live vaccines in mice provide key information for safety assessment. We examined the bacterial loads at the site of vaccination and in draining lymph nodes (dLNs), spleen, and lungs over 90 days in s.c.-vaccinated mice that received either a standard or vitamin B 6 -enriched diet. BCG disseminated from the injection site to dLNs and spleen, where the bacterial counts remained relatively stable until the end of the experiment, in contrast to BCG ⌬ureC:: :hly, and BCG ⌬ureC::hly ⌬pdx1 in mice on a normal diet or vitamin B 6 -enriched nutrition. Vaccines (10 6 CFU) were administered s.c. at the tail base. Independent from vitamin B 6 administration, BCG ⌬ureC::hly and BCG ⌬ureC::hly ⌬pdx1 were not detected in lungs. Shown are means Ϯ standard deviations (SD) (n ϭ 5) analyzed using two-way analysis of variance (ANOVA) and Tukey's post hoc test. Significant statistical differences between BCG ⌬ureC::hly and BCG ⌬ureC::hly ⌬pdx1 groups are indicated as follows: *, P Ͻ 0.05; **, P Ͻ 0.01; ***, P Ͻ 0.001; ****, P Ͻ 0.0001. Experiments were performed twice.
hly, which was cleared from these organs after 45 or 28 days, respectively (Fig. 1C ). These observations are in line with previous experiments where BCG persisted for up to 120 days in dLNs and 90 days in the spleen, while at 60 days postvaccination, BCG ⌬ureC::hly was undetectable (26) . BCG was the only vaccine tested that disseminated to lungs (Fig. 1C) . The survival of BCG and BCG ⌬ureC::hly in mice remained independent of dietary vitamin B 6 levels. Intriguingly, BCG ⌬ureC::hly ⌬pdx1 did not persist beyond 45 days (vaccination site) or 14 days (dLNs and spleen) (Fig. 1C) , suggesting that its attenuation is determined by the pdx1 deletion rather than ureC disruption or Hly expression. Vitamin B 6 supplementation restored the persistence of the auxotrophic construct to that of the parental BCG ⌬ureC::hly in dLNs but not at the site of vaccination or in the spleen (Fig. 1C) . We conclude that knockout of pdx1 profoundly attenuated BCG constructs in mice. Elevated vitamin B 6 administration could partially compensate for reduced persistence but did not achieve complete chemical complementation in vivo.
BCG ⌬ureC::hly ⌬pdx1 is safer than parental BCG ⌬ureC:: hly in immunodeficient mice. Having demonstrated that the deletion of pdx1 profoundly attenuated BCG in immunocompetent mice ( Fig. 1) , we went on to determine the safety of BCG ⌬ureC:: hly ⌬pdx1 in mice with severe combined immunodeficiency (SCID). Groups of animals were s.c. vaccinated with 10 6 CFU of the constructs under investigation. The SCID mice receiving the parental BCG ⌬ureC::hly survived significantly longer than the BCG-vaccinated group, confirming the superior safety of the recombinant construct (Fig. 2) (22) . When the experiment was terminated 500 days postvaccination, the survival of groups that received BCG ⌬ureC::hly ⌬pdx1 (with or without vitamin B 6 supplementation) or phosphate-buffered saline (PBS) was significantly improved over that of mice receiving BCG ⌬ureC::hly, demonstrating profound attenuation of the auxotrophic construct in immunodeficient mice (Fig. 2) .
Vitamin B 6 controls acquired but not innate immunity induced by BCG ⌬ureC::hly ⌬pdx1. The systemic innate immune responses measured by cytokine secretion were independent of dietary vitamin B 6 levels (Fig. 3A) . However, 24 h following inoculation, BCG ⌬ureC::hly ⌬pdx1 showed a more pronounced stimulation of the inflammatory mediators interleukin-6 (IL-6), granulocyte colony-stimulating factor (G-CSF), keratinocyte cytokine (KC), and macrophage inflammatory protein-1␣ (MIP-1␣) than BCG SSI 1331 and BCG ⌬ureC::hly, which depended on pdx1 deletion (G-CSF and MIP-1␣) or vitamin B 6 supplementation (IL-6 and KC) (Fig. 3A) . In order to detect mycobacteriumspecific T cells, we stimulated splenocytes with antigen ex vivo, in the presence of a CD40-blocking monoclonal antibody. Antigenspecific CD4 T cells, which consequently upregulated CD154 under these conditions, were then enumerated by flow cytometry and compared to those from naive controls (27) . Twentyeight days postvaccination, the absolute numbers and proportions of antigen-specific CD4 T cells were increased in mice vaccinated with BCG ⌬ureC::hly, as well as in mice vaccinated with BCG ⌬ureC::hly ⌬pdx1 under vitamin B 6 supplementation ( Fig. 3B and C). The proportion of CD4 T cells secreting gamma interferon (IFN-␥) and tumor necrosis factor alpha (TNF-␣) was also increased in mice vaccinated with BCG ⌬ureC::hly and in the supplemented auxotrophic-strain-vaccinated groups compared to the proportion in naive mice (Fig. 3B ). This immune response persisted for 3 months postvaccination. We conclude that the improved survival of the auxotrophic BCG ⌬ureC::hly ⌬pdx1 strain due to the administration of vitamin B 6 supported the generation of memory T cells, which persist after clearance of the vaccine strain ( Fig. 1C and 3D ). Vaccination also generated long-lived, IgG-secreting plasma cells, which homed to bone marrow. These cells were detected 3 months postvaccination with either BCG ⌬ureC::hly or vitamin B 6 -supplemented BCG ⌬ureC::hly ⌬pdx1 (Fig. 3E) . Thus, adaptive immunity, particularly the generation of antigen-specific CD4 T cells and B cells in response to mycobacterial antigens, depended on the persistence of the vaccine strains, and the persistence of the auxotrophic strain could be regulated by exogenous administration of vitamin B 6 .
Vitamin B 6 controls early protection against M. tuberculosis in BCG ⌬ureC::hly ⌬pdx1-vaccinated mice. In order to assess the protective capacity of BCG ⌬ureC::hly ⌬pdx1, we aerosol challenged mice with the M. tuberculosis laboratory strain H37Rv 90 days postvaccination. The bacterial burdens in lungs and spleens were determined at 30 and 180 days postinfection (Fig. 4A ). As in previous experiments (23, 26) , BCG ⌬ureC::hly consistently induced better protection than BCG (Fig. 4B) . The early protection provided by BCG ⌬ureC::hly ⌬pdx1 depended on vitamin B 6 supplementation and was comparable to that induced by BCG but was completely lost at 180 days postinfection (Fig. 4B) . Presumably, the vitamin B 6 -dependent persistence of the construct in dLNs and spleen (Fig. 1C) was not sufficient to induce long-lasting protection. We conclude that a single immunization with BCG ⌬ureC::hly ⌬pdx1 does not suffice for longterm protection against aerogenic M. tuberculosis infection in mice.
Prime-boost vaccination improves the efficacy of BCG ⌬ureC::hly ⌬pdx1. The fast clearance of the auxotrophic vaccine construct from mouse organs (Fig. 1C ) led us to hypothesize that the protective capacity of BCG ⌬ureC::hly ⌬pdx1 could be improved by homologous prime-boost immunization. After vaccination, mice were aerosol challenged with the M. tuberculosis laboratory strain H37Rv or bacilli of the clinically relevant Beijing/W lineage (28) . Mice vaccinated with BCG ⌬ureC::hly ⌬pdx1 and fed a normal diet showed bacterial burdens in lungs equal to those of animals vaccinated with BCG ( Fig. 5A and B) . The early protection (day 30) in lungs provided by the auxotrophic strain consis- . Data shown were analyzed using the Mantel-Cox log-rank test. *, P Ͻ 0.05; **, P Ͻ 0.01; ***, P Ͻ 0.001; ****, P Ͻ 0.0001. Experiment was performed twice.
tently depended on vitamin B 6 -enriched nutrition and, for Beijing/W-infected groups, was equal to the protection provided by the parental BCG ⌬ureC::hly and significantly better than that of BCG (Fig. 5A ). Homologous prime-boost vaccination with BCG ⌬ureC::hly ⌬pdx1 improved the long-term efficacy against M. tuberculosis H37Rv to the level afforded by BCG and performed significantly better than the mock-vaccinated control group against Beijing/W infection ( Fig. 5A and B) . The protection of the lung at late time points (180 days for M. tuberculosis H37Rv and 160 days for M. tuberculosis Beijing/W) remained independent from vitamin B 6 supplementation ( Fig. 5A and B) . The results obtained from the spleen were less pronounced and often The proportion of IgG-secreting cells in bone marrow measured by ELISPOT 3 months postvaccination. One-way ANOVA followed by Bonferroni's posttest was used for statistical analysis. *, P Ͻ 0.05; **, P Ͻ 0.01; ***, P Ͻ 0.001; ****, P Ͻ 0.0001; n ϭ 3 or 4. Representative data from two independent experiments are shown.
lacked statistical significance. Taken together, homologous prime-boost immunization improved the efficacy afforded by BCG ⌬ureC::hly ⌬pdx1 compared to that of single prime vaccination and consistently depended on a dietary vitamin B 6 supply at early time points following M. tuberculosis challenge.
DISCUSSION
The increasing realization that the current BCG vaccine provides insufficient protection against TB, even in newborns, prompted us to develop a recombinant BCG, BCG ⌬ureC::hly, which had improved efficacy and safety in preclinical models and is currently undergoing phase II clinical assessment (29) . The increasing proportion of immunocompromised vaccinees has now led us to further modify this construct toward a superior safety profile by rendering it auxotrophic for vitamin B 6 . Several auxotrophic mycobacterial mutants have been described (15, 30) . Due to their inability to synthesize certain amino acids or cofactors, such mutants rely on uptake of the missing factor in order to survive. During infection, mycobacteria reside in the phagosome of antigen-presenting cells, notably, macrophages (31) . The phagosome is an organelle specialized in the eradication of microbial intruders and, therefore, poor in nutrients but rich in reactive radicals and hydrogen ions (31) . Pathogenic mycobacteria can survive and replicate in this hostile environment and eventually egress to the host cell cytosol (32, 33) . In contrast, auxotrophic mutants of M. tuberculosis are severely attenuated in vivo, demonstrating that infected host cells do not provide sufficient concentrations of the respective factors to overcome deficient persistence (8, 9, 11, 15) . The cytosolic concentration of PLP, the bioactive form of vitamin B 6 , in eukaryotic cells is regulated by "metabolic trapping," a process in which the uncharged vitamers become phosphorylated upon entering cells by passive diffusion (34) . As a result, leakage of the negatively charged B 6 vitamer phosphoesters through biological membranes is prevented. Indeed, PLP could not restore the growth of M. tuberculosis ⌬pdx1 in cultures, confirming the absence of a dedicated uptake system (15) . As a corollary, mycobacterial pdx1 mutants are attenuated in mice (Fig. 1C) (15) . Intriguingly, when we fed mice an~10-fold daily dose of vitamin B 6 -more than 10,000-fold below the 50% lethal dose reported for mice (35)-the persistence of BCG ⌬ureC::hly ⌬pdx1 in dLNs improved and the vaccine candidate was as immunogenic as its parental BCG ⌬ureC::hly and superior to BCG (Fig. 1C) . Clearance of the auxotrophic strain at the site of vaccination and in the spleen was independent of vitamin B 6 supplementation, suggesting that the availability of the cofactor could not be raised by elevated uptake into these organs. Intriguingly, the superiority of the safety profile of BCG ⌬ureC::hly over that of canonical BCG in SCID mice that serve as an immunodeficiency model was further improved by pdx1 deletion and remained independent of vitamin B 6 supplementation (Fig. 2) .
The assessment of blood serum cytokine concentrations as indicators of innate immunity suggests a proinflammatory phenotype for BCG ⌬ureC::hly ⌬pdx1 compared to that of its parental strain (Fig. 3A) . While the IL-6 and KC release induced by the auxotrophic strain depended on a vitamin B 6 -enriched diet, the increased levels of G-CSF and MIP-1␣ were related to the pdx1 mutation. Vitamin B 6 supplementation left these innate immune parameters in response to BCG or BCG ⌬ureC::hly unaffected (Fig. 3A) , thus linking our observations to the persistence of the auxotrophic construct. While inflammatory mediators of innate immunity were stimulated by the attenuated strain, long-lasting antigen-specific T cell responses were only induced when bacterial persistence had been re-established by vitamin B 6 supplementation. This is particularly relevant as CD4 T cell responses are thought to be an important component of protection against pulmonary TB (36) and are frequently harnessed as biomarkers of vaccine efficacy (37, 38) . Although the role of antibodies in protection remains controversial, the ability of vitamin B 6 supplementation to induce long-lived plasma cells supports the importance of vaccine persistence for effective stimulation of adaptive immune responses.
The blood serum concentrations of B6 vitamers (pyridoxal 5-phosphate, 5 to 111 nM; 4 to pyridoxic acid, 6 to 93 nM; and pyridoxal, 3 nM) vary considerably in humans on a normal diet but stabilize (pyridoxal 5-phosphate,~350 nM; 4-pyridoxic acid, 1,000 nM; and pyridoxal,~700 nM) 3 days after daily intake of 40 mg of vitamin B 6 (39) . Approximately 70 to 80% of overall vitamin B 6 is found bound to glycogen phosphorylase in muscles (40) . The upper tolerated dose of the vitamin in adults is 100 mg/ day (41) . Vitamin B 6 deficiency affects innate and acquired immune responses, but physiological functions can be restored by standard supplementation with the cofactor, while larger doses were not more beneficial (42) . Accordingly, increasing dietary vitamin B 6 supplementation beyond sufficient doses did not influence either the protective efficacy of BCG and BCG ⌬ureC::hly in a murine challenge model or the course of M. tuberculosis infection per se in naive mice (see Fig. S2 and S3 in the supplemental material). Therefore, the early protection induced by BCG ⌬ureC::hly ⌬pdx1 consistently depended on the persistence of the construct under the control of vitamin B 6 supplementation (Fig. 4B ). Mice immunized with the auxotrophic strain in a homologous prime-boost vaccination scheme (Fig. 4A) maintained the vitamin B 6 -related differences but revealed improved protection, to a degree similar to that of parental BCG ⌬ureC::hly 30 days postchallenge with M. tuberculosis Beijing/W (Fig. 5A and B) . Whether protection could be further improved by a second booster vaccination remains the topic of future studies.
Altogether, we demonstrate for the first time that a nutritional supplement, namely, the small-molecule vitamin B 6 , controls the persistence of a recombinant BCG auxotroph in vivo. Most importantly, this translated into vitamin B 6 dependency of acquired early immune protection in response to the auxotrophic construct. This principle will enable the development of safer BCG vaccines that are urgently needed for the growing proportion of immunocompromised individuals among vaccinees.
MATERIALS AND METHODS
Bacterial strains and growth conditions. BCG (BCG SSI 1331; ATCC 35733; American Type Culture Collection), BCG ⌬ureC::hly (BCG Prague background) (22, 23) , M. tuberculosis H37Rv (ATCC 27294), and Beijing/W (RIVM 17919, isolated in Mongolia) were maintained in Middlebrook 7H9 medium (Becton, Dickinson) supplemented with 0.2% glycerol, 0.05% Tween 80, 10% albumin-dextrose-catalase supplement (Becton, Dickinson), in Sauton's minimal medium (0.5 g/liter KH 2 PO 4 , 0.5 MgSO 4 , 2 g/liter citric acid, 0.05 g/liter ferric ammonium citrate, 4 g/ liter asparagine, 6% glycerol, 0.05% Tween 80, pH 6.8), or on Middlebrook 7H11 agar (Becton, Dickinson) containing 10% (vol/vol) oleic acid-albumin-dextrose-catalase enrichment (Becton, Dickinson) and 0.2% glycerol. Mycobacterial cultures were grown to mid-log phase in 1-liter roller bottles (450 cm 2 ) at 37°C and 2 rpm. For in vitro growth studies, mycobacteria were grown in Sauton's minimal medium supplemented with 5 M pyridoxine. Cultures were pelleted at 3,200 rpm and washed three times prior to resuspension in fresh Sauton's medium with or without pyridoxine. The optical density at 600 nm (OD 600 ) was determined daily. For vaccine stock preparations, bacilli were collected by centrifugation at 3,200 rpm, washed with phosphate-buffered saline (PBS), and stored at Ϫ80°C as a suspension in PBS--10% glycerol. Prior to vaccination, vials were thawed and cells harvested and resuspended in an appropriate volume of PBS. For CFU enumeration, serial dilutions were performed in PBS--0.05% Tween 80 (PBST) and plated on Middlebrook 7H11 agar. The plates were incubated at 37°C for 3 to 4 weeks prior to CFU counting.
Generation of BCG ⌬ureC::hly ⌬pdx1 and genetic complementation. The pdx1 gene of BCG ⌬ureC::hly was disrupted as described earlier for M. tuberculosis (15) . Briefly, 1-kb fragments flanking pdx1 were amplified by PCR using the specific oligonucleotides ko5=pdx1.fwd (5= TAC TTAAGCGGGTCAGCGGGCATTCC 3=)/ko5=pdx1.rev (5= ATTCTAGA CCGGGGTGACAACGTCCATGAT 3=) and ko3=pdx1.fwd (5= TAAAGC TTTGTGCTGGCCAAGGTGTCG 3=)/ko3=pdx1.rev (5= ATACTAGTCG ACCCGTGGAACGCTCACAG 3=) (restriction sites are underlined) and inserted into pYUB854 (43). The knockout plasmid was then electroporated into BCG ⌬ureC::hly, and transformants were selected on Middlebrook 7H11 agar (contains vitamin B 6 ) supplemented with 80 g/ml hygromycin B (Roche). The hygromycin resistance cassette was subsequently removed by standard methods described previously (44) . Sitedirected mutagenesis and selection marker removal were confirmed by automated sequencing of the pdx1 region. For genetic complementation, pdx1, including its putative promoter, was amplified by PCR (comppdx1.fwd [5= GCTGGTACCAGGGAAAGGTTGCCGATG 3=] and comppdx1.rev [5= GCTGGTACCAGGGAAAGGTTGCCGATG 3=]) and inserted into the integrative vector pMV306 (45) . BCG ⌬ureC::hly ⌬pdx1 was then electroporated with the complementing vector, and transformants were selected on Middlebrook 7H11 agar containing 25 g/ml kanamycin (Sigma-Aldrich). Multiplex cytokine assays. The Bio-Rad mouse cytokine 23-plex panel was used for analysis of cytokines in sera of vaccinated mice. In all multiplex assays, the volume of the coupled beads, detection antibodies, and streptavidin-phycoerythrin (PE) conjugate was halved and topped up with the appropriate buffer. The assays were otherwise performed according to the manufacturer's instructions. The assay plates were read using a Bio-Plex 200 instrument (Bio-Rad).
Flow cytometry. Cytokine-secreting antigen-specific T cells were enumerated as described previously (27) . In brief, single-cell suspensions of splenocytes were cultured in complete RPMI 1640 medium (Gibco) supplemented with 10% heat-inactivated fetal calf serum (FCS; Gibco), 100 U/ml penicillin, 100 U/ml streptomycin, 2 mM L-glutamine, and 50 M 2-mercaptoethanol (Sigma) for 14 h along with 10 g/ml M. tuberculosis H37Rv whole-cell lysate in the presence of 2 g/ml anti-CD40 blocking antibody (HM40-3; BioLegend) and 0.5 g/ml PE-conjugated anti-CD154 (clone MR1; BioLegend). Ten micrograms/milliliter Brefeldin A (eBioscience) was added for the final 3 h of culture. After stimulation, cells were washed and stained on ice in PBS--2% FCS with fluorescent antibodies against cell surface markers CD4, CD3, CD8 (BD Biosciences), and CD62L (BioLegend), followed by fixation and permeabilization with the Cytofix/Cytoperm kit (BD Biosciences) according to the manufacturer's instructions. Intracellular cytokines were detected with antibodies against IFN-␥ and TNF-␣ (BD Biosciences). Cells were analyzed on an LSRII cytometer using Diva (Becton, Dickinson) and FlowJo software (Tree Star).
Enzyme-linked immunosorbent spot assay (ELISPOT). Ninety-sixwell multiscreen filtration plates (Millipore) were soaked with 30% ethanol and then rinsed and coated overnight at 4°C with 5 g/ml polyclonal goat anti-mouse IgMϩIgGϩIgA (Millipore). The following day, the plates were washed and blocked with PBS--3% bovine serum albumin for 2 h at 37°C. Serial dilutions of single-cell suspensions of bone marrow were cultured on plates for 3 h at 37°C in medium prepared as described above. Cells were washed off, and the plates incubated with anti-mouse IgG-alkaline phosphatase (SouthernBiotech) for 1 h at 37°C. Finally, plates were washed with water before detection of IgG ϩ spots with 1-Step NBT-BCIP (nitro-blue tetrazolium chloride--5-bromo-4-chloro-3=-indolyphosphate p-toluidine salt) substrate (Thermo Scientific).
Mouse strains and housing conditions. Mice were 9 to 10 weeks old at the beginning of experiments. Female BALB/c (Janvier) were housed in groups of 5 or 6 in individually ventilated cages. Drinking water and food pellets (Ssniff R/M-H autoclavable, 0.032 mg pyridoxine per g) were offered ad libitum. Experimental groups that were maintained with vitamin B 6 -enriched nutrition received drinking water with 0.1 mg/ml pyridoxine hydrochloride (Sigma-Aldrich). Female SCID mice (CB-17/Icr-Prkdc-SCID /Rj; Janvier) were kept under sterile conditions. All experimental procedures involving mice were approved by the State Office for Health and Social Services, Berlin, Germany (Landesamt für Gesundheit und Soziales Berlin, LAGeSo). Mice were sacrificed by cervical dislocation, and all efforts were made to minimize suffering and pain. Dissemination, protective efficacy, and safety of BCG and derivatives in mice. Mice were s.c. immunized in the tail base with 10 6 CFU BCG or recombinant derivative strains. At designated time points postvaccination, mice were sacrificed, and then a 1-cm 2 skin portion at the side of injection and the dLNs, spleen, and lungs of each animal were aseptically removed and homogenized in PBS--0.05% Tween 80 prior to CFU enumeration. For protective efficacy studies, mice were aerosol challenged 90 days postvaccination with 100 to 200 CFU of M. tuberculosis. At designated time points, lungs and spleens were aseptically removed, homogenized in PBS--0.05% Tween 80, and plated in serial dilutions onto Middlebrook 7H11 agar for CFU enumeration. After vaccination, SCID mice did not receive further experimental manipulations. Weight was monitored weekly, and mice were euthanized when weight loss exceeded 20%.
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